Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 | P25440 | 18/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 18/20 | 1.00 |
| ▸ | TRIM24 | O15164 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TAF1 | P21675 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 1/20 | 1.00 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 1.00 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 1.00 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11978889 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL1907498 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL22704705 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL1906368 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL19985767 | 0.93 | BRD4 (0.87) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL16774251 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL16774302 | 0.92 | BRD4 (0.86) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL223735 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL15981317 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL221384 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025049555-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115702026-A | Macrocyclic compounds and methods of use thereof | 基因泰克公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-114377137-A | Combination of LSD1 inhibitors for the treatment of hematologic malignancies | 奥莱松基因组股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-109462980-B | Combination of LSD1 inhibitors for the treatment of hematologic malignancies | 奥莱松基因组股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | BRD4 537/4885BRD2 2140/4885BRD3 1209/4885 |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | BET1, BRD2, BRD4 | BRD4 3/4885BRD2 2/4885BRD3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.